课题基金 / 基金详情

Response to and protection by gp96SIVIg/TNFSF13 and gp96SIVIg/TNFSF15 vaccines

Response to and protection by gp96SIVIg/TNFSF13 and gp96SIVIg/TNFSF15 vaccines
gp96SIVIg/TNFSF13 和 gp96SIVIg/TNFSF15 疫苗的反应和保护
批准号:
8198211
负责人:
ECKHARD R PODACK
金额:
$37.17万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-09-01 至 2014-08-31

项目摘要

项目成果

ECKHARD R PODACK的其他基金

相似基金

相关文献

中文摘要
翻译
我们的目标是确定我们是否可以通过诱导疫苗诱导的SIV传播来“超越”SIV传播 猕猴(Rm)的免疫应答。两种新型疫苗,gp96-LG-SIV和HPV-SIV将被 分别经腹膜腔(IP)和阴道途径给药或联合用药 并且没有SIV gp120。我们之前对这些疫苗的经验是,这两种疫苗都能诱导强大的粘膜免疫 通过不同的机制作出反应。我们假设,粘膜和组织的动力学和性质 全身免疫反应将决定接种疫苗的动物经阴道后感染的结果 SIV挑战赛。先天和获得性免疫反应将针对每个观察到的结果进行表征 了解免疫保护的相关因素。免疫学研究将通过以下方式得到加强 伴随着基因表达谱、翻译后修饰、病毒多样化的研究 以及对病毒库的估计。我们的目标是了解对SIV挑战的自然反应 被疫苗改变,导致流产的SIV感染或减弱病毒传播并降低峰值 接种疫苗的动物与对照动物的病毒血症。我们关注的是阴道局部免疫力以及 区域淋巴结、肠道和全身免疫反应。我们提出以下目标来评估 使用SIVmac251前后未接种和接种RM疫苗。目标1:研究先天 免疫反应、病毒整合和病毒库和目标2:研究获得性免疫 CD_4、CD_8 T细胞和B细胞应答。将进行的研究将包括调查职位 疫苗接种/病毒前挑战,在日食阶段和疫苗接种后60天 和未接种疫苗的动物。详尽的研究包括宿主限制因子APOBEC3G,病毒库, 病毒多样化,NK细胞,伽马-德尔塔T细胞,适应性SIV特异性T和B细胞表型和 功能图谱将在与基因组学相联系的仔细协调和详尽的分析中确定, 蛋白质组学,组织病理学和免疫学分析,以提供对宿主- SIV与疫苗的相互作用及相关因素增强了免疫保护作用。
英文摘要
Our goal is to determine if we can "outpace" SIV transmission through the induction of a vaccine induced immune response in Rhesus macaques (RM). Two novel vaccines, the gp96-lg-SIV and the HPV-SIV will be administered through intraperitoneal (IP) and intravaginal routes respectively singly or in combination with and without SIV gp120. Our prior experience with these vaccines is that both elicit potent mucosal immune responses through different mechanisms. We hypothesize that the kinetics and nature of mucosal and systemic immune responses will determine the outcome of infection in vaccinated animals following vaginal SIV challenge. Innate and adaptive immune responses will be characterized for each observed outcome to get an understanding of correlates of immune protection. Immunologic studies will be enhanced by concomitant investigation of gene expression profiling, post translational modification, virus diversification and estimates of viral reservoir. Our goal is to understand how natural responses to SIV challenge are altered by vaccines that result in aborted SIV infection or attenuated virus dissemination and lowered peak viremia in vaccinated versus control animals. We are focusing on the vaginal local immunity as well as regional lymph nodes, gut and systemic immune responses. We propose the following aims to evaluate unvaccinated and vaccinated RM pre- and post- challenge with SIVmac251. Aim 1: to investigate innate immune responses, virus integration and virus reservoirs and Aim 2: to investigate adaptive immune responses of CD4 and CD8 T cells and B cells. Studies to be performed will include investigations post vaccination /pre-virus challenge, during the eclipse phase and at 60 days post virus challenge in vaccinated and unvaccinated animals. Exhaustive studies including host restriction factor Apobec3G, viral reservoir, virus diversification, NK cells, gamma-delta T cells, and adaptive SIV specific T and B cell phenotypic and functional profiles will be determined in a carefully coordinated and exhaustive analysis linking genomics, proteomics, histopathology and immunologic analyses to provide insight into earliest mechanisms of host- SIV interaction and correlates of vaccine incused immune protection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mpeg1 in Innate Immunity
Generation of gp96SIVIg/TNFSF13 and gp96SIVIg/TNFSF15 vaccinesVaccines
Mechanisms of mucosal protection by HPV-SIV and gp96-lg-SIV vaccines
Induction of mucosal SIV immunity in non human primates by secreted Hsp-Gp96
海外基金